UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 32

Sortiert nach

Preventing, identifying, and managing medication-related osteonecrosis of the jaw: a practical guide for nurses and other allied healthcare professionals

Supportive care in cancer, 2020-09, Vol.28 (9), p.4019-4029

2020

Link zum Volltext

Verfügbarkeit prüfen

Role of Axillary Clearance After a Tumor-Positive Sentinel Node in the Administration of Adjuvant Therapy in Early Breast Cancer

Journal of clinical oncology, 2010-02, Vol.28 (5), p.731-737

2010

Link zum Volltext

Verfügbarkeit prüfen

Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review

BMC cancer, 2017-11, Vol.17 (1), p.798-798, Article 798

2017

Link zum Volltext

Verfügbarkeit prüfen

The Healthcare Professionals’ Perspective on Impact and Actions Taken Following Severe Infusion Reaction Events in Oncology Centers in Europe

Drugs - Real World Outcomes, 2020-06, Vol.7 (2), p.119-130

2020

Link zum Volltext

Verfügbarkeit prüfen

Systematic review and meta-analysis on the proportion of patients with breast cancer who develop bone metastases

Critical reviews in oncology/hematology, 2017-07, Vol.115, p.67-80

2017

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Treated with Panitumumab in the ASPECCT Study

Clinical cancer research, 2019-02, Vol.25 (4), p.1216-1225

2019

Link zum Volltext

Verfügbarkeit prüfen

Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma

International journal of colorectal disease, 2017-08, Vol.32 (8), p.1179-1190

2017

Link zum Volltext

Verfügbarkeit prüfen

Management of adverse events during treatment of gastrointestinal cancers with epidermal growth factor inhibitors

Critical reviews in oncology/hematology, 2017-06, Vol.114, p.102-113

2017

Link zum Volltext

Verfügbarkeit prüfen

Panitumumab‐based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials

International journal of cancer, 2019-07, Vol.145 (2), p.576-585

2019

Link zum Volltext

Verfügbarkeit prüfen

Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials

Journal of cancer research and clinical oncology, 2018-02, Vol.144 (2), p.321-335

2018

Link zum Volltext

Verfügbarkeit prüfen

Characteristics and response outcomes of long-term survivors in studies of first-line panitumumab for metastatic colorectal cancer

Annals of oncology, 2017-06, Vol.28, p.iii112-iii113

2017

Link zum Volltext

Verfügbarkeit prüfen

Management of EGFR Inhibitor-induced Skin Toxicity and Factors Impacting Patients’ Adherence to Skin Toxicity Treatment: Health Care Provider and Patient Surveys in European Oncology Centers

Clinical colorectal cancer, 2020-06, Vol.19 (2), p.100-108.e9

2020

Link zum Volltext

Verfügbarkeit prüfen

European follow-up of incorrect biomarker results for colorectal cancer demonstrates the importance of quality improvement projects

Virchows Archiv : an international journal of pathology, 2019-07, Vol.475 (1), p.25-37

2019

Link zum Volltext

Verfügbarkeit prüfen

Rechallenge with EGFR inhibitors in patients with metastatic colorectal cancer: effect on outcomes

Annals of oncology, 2017-06, Vol.28, p.iii113-iii113

2017

Link zum Volltext

Verfügbarkeit prüfen

Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer

British journal of cancer, 2016-11, Vol.115 (10), p.1215-1222

2016

Link zum Volltext

Verfügbarkeit prüfen

Prospective Observational Cohort Study to Describe the Use of Panitumumab in Combination with Chemotherapy in Real-World Clinical Practice for Patients with Wild-Type RAS mCRC

Advances in therapy, 2019-03, Vol.36 (3), p.670-683

2019

Link zum Volltext

Verfügbarkeit prüfen

Treatment guidelines for adjuvant breast cancer are moving toward double standards: one for the rich and one for the poor

Journal of clinical oncology, 2005-12, Vol.23 (36), p.9436-9437

Demonty, Gaston

2005

Link zum Volltext

Verfügbarkeit prüfen

PACS 01 trial: questions about patients' characteristics and reported results

Journal of clinical oncology, 2007-05, Vol.25 (15), p.2143; author reply 2143-2143

2007

Link zum Volltext

Verfügbarkeit prüfen

Author Correction: Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials

Journal of cancer research and clinical oncology, 2018-04, Vol.144 (4), p.795-797

2018

Link zum Volltext

Verfügbarkeit prüfen

Exploratory pooled analysis evaluating the effect of sequence of biological therapies on overall survival in patients with RAS wild-type metastatic colorectal carcinoma

ESMO open, 2018, Vol.3 (2), p.e000297-e000297, Article e000297

2018

Link zum Volltext

Verfügbarkeit prüfen

Progress and new standards of care in the management of HER-2 positive breast cancer

European journal of cancer (1990), 2007-02, Vol.43 (3), p.497-509

2007

Link zum Volltext

Verfügbarkeit prüfen

Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status

Clinical colorectal cancer, 2018-03, Vol.17 (1), p.50-57.e8

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 32

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(31)
Mit Volltextzugriff
(32)

Publikationsform

Artikel
(31)
Buchkapitel
(1)

Sprache

Englisch
(32)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(26)
Science & Technology
(26)
Oncology
(23)
Humans
(18)
Female
(15)
Middle Aged
(11)
Adult
(10)
Aged
(9)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(9)
Colorectal Neoplasms - Drug Therapy
(8)
Metastatic Colorectal Cancer
(8)
Panitumumab
(8)
Treatment Outcome
(8)
Tumors
(8)
Breast Neoplasms - Drug Therapy
(7)
Chemotherapy
(7)
Male
(7)
Medicine
(7)
Medicine & Public Health
(7)
Aged, 80 And Over
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Preventing, identifying, and managing medication-related osteonecrosis of the jaw: a practical guide for nurses and other allied healthcare professionals

Role of Axillary Clearance After a Tumor-Positive Sentinel Node in the Administration of Adjuvant Therapy in Early Breast Cancer

Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review

The Healthcare Professionals’ Perspective on Impact and Actions Taken Following Severe Infusion Reaction Events in Oncology Centers in Europe

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

Systematic review and meta-analysis on the proportion of patients with breast cancer who develop bone metastases

Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Treated with Panitumumab in the ASPECCT Study

Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma

Management of adverse events during treatment of gastrointestinal cancers with epidermal growth factor inhibitors

Panitumumab‐based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials

Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials

Characteristics and response outcomes of long-term survivors in studies of first-line panitumumab for metastatic colorectal cancer

Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC – The ETOP/EORTC SPLENDOUR and AMGEN-249 trials

Management of EGFR Inhibitor-induced Skin Toxicity and Factors Impacting Patients’ Adherence to Skin Toxicity Treatment: Health Care Provider and Patient Surveys in European Oncology Centers

European follow-up of incorrect biomarker results for colorectal cancer demonstrates the importance of quality improvement projects

Rechallenge with EGFR inhibitors in patients with metastatic colorectal cancer: effect on outcomes

Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer

Prospective Observational Cohort Study to Describe the Use of Panitumumab in Combination with Chemotherapy in Real-World Clinical Practice for Patients with Wild-Type RAS mCRC

Treatment guidelines for adjuvant breast cancer are moving toward double standards: one for the rich and one for the poor

Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial

PACS 01 trial: questions about patients' characteristics and reported results

Author Correction: Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials

Exploratory pooled analysis evaluating the effect of sequence of biological therapies on overall survival in patients with RAS wild-type metastatic colorectal carcinoma

Progress and new standards of care in the management of HER-2 positive breast cancer

Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status

Suchergebnisse filtern